Last reviewed · How we verify

Infergen and ribavirin — Competitive Intelligence Brief

Infergen and ribavirin (Infergen and ribavirin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha and nucleoside analog combination. Area: Virology/Hepatology.

marketed Interferon alpha and nucleoside analog combination Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Infergen and ribavirin (Infergen and ribavirin) — Kadmon Corporation, LLC. Infergen (interferon alfacon-1) is a synthetic interferon that activates innate immune responses to inhibit viral replication, while ribavirin is a nucleoside analog that directly inhibits viral RNA synthesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Infergen and ribavirin TARGET Infergen and ribavirin Kadmon Corporation, LLC marketed Interferon alpha and nucleoside analog combination Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha and nucleoside analog combination class)

  1. Kadmon Corporation, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Infergen and ribavirin — Competitive Intelligence Brief. https://druglandscape.com/ci/infergen-and-ribavirin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: